# Tissue Repair and Recovery Research: What the Evidence Shows **The best peptides for recovery** are usually presented as a ranked list. This page takes a different approach: it groups the compounds most often studied in tissue-repair research by the mechanism each one acts on, and states plainly how far the evidence behind each mechanism actually extends. Every compound referenced here is supplied for laboratory research only. That framing matters, because the four compound classes below are not interchangeable and are not ranked against one another. Each was characterised in a different body of literature, against different injury models, at different levels of rigour. Grouping them by mechanism makes those differences visible in a way an ordered list conceals. ## Why connective tissue dominates the repair literature Most tissue-repair research concentrates on tendon, ligament and fascia rather than skeletal muscle, and the reason is metabolic. Researchers observed that skeletal muscle repairs comparatively quickly: satellite cells activate within hours of mechanical damage, and acute fibre disruption largely resolves across one to two weeks in animal models given adequate nutrition and rest. Connective tissue behaves differently. Tendon is metabolically sparse, its blood supply is limited, and collagen turnover is slow. Preclinical work indicates that meaningful tendon remodelling takes three to six months under ordinary conditions. That mismatch — muscle recovering across days, connective tissue across months — is what makes tendon and ligament models the dominant setting for recovery-compound research. A second theme concerns inflammatory resolution. Acute inflammation is the first phase of healing, and findings indicated that suppressing it outright can degrade the quality of the eventual repair. Persistent low-grade inflammation, by contrast, is associated in animal models with a tissue environment less favourable to efficient remodelling. Much of the research interest in these compounds sits in that gap, between inflammation that is necessary and inflammation that fails to resolve. ## Four mechanisms under investigation | Compound | Primary reported mechanism | Predominant model | Depth of evidence | | --- | --- | --- | --- | | BPC-157 | Angiogenesis; fibroblast activation | Rodent tendon, ligament and gastrointestinal | Largest preclinical body; direct controlled human data limited | | TB-500 | Monomeric actin binding; cell migration; systemic distribution | Rodent soft tissue and cardiac | Moderate preclinical; direct controlled human data limited | | GHK-Cu | Gene expression affecting collagen and elastin synthesis | In vitro and rodent, weighted toward dermal | Moderate; concentrated outside musculoskeletal repair | | Ipamorelin / CJC-1295 | Pulsatile GH release; downstream IGF-1 signalling | Animal studies plus human pharmacokinetic work | Human pharmacokinetic data; little controlled repair-outcome data | ### Angiogenesis and fibroblast activation — BPC-157 BPC-157 is a synthetic 15-amino-acid sequence derived from a gastric protective protein, and it carries the largest preclinical literature of the four. In rodent models researchers observed upregulation of VEGF and new blood vessel formation at injury sites, alongside fibroblast activation and deposition of a collagen framework. Angiogenesis is the most consistently reported finding across tendon, ligament and muscle models. Our summary of that literature, with citations, is the [BPC-157 preclinical research overview](https://portaltowellness.net/research/bpc-157-preclinical-research/) , and the material itself is listed on the [BPC-157 page](https://portaltowellness.net/bpc-157/) . A separate body of gastrointestinal work reported effects on intestinal barrier integrity in rodents. That is worth noting for context: the gastrointestinal models are where BPC-157 was originally characterised, and the soft-tissue work followed later. ### Actin regulation and cell migration — TB-500 TB-500 is a synthetic fragment related to Thymosin Beta-4, a protein present at high concentration in platelets and wound fluid. Its reported mechanism is structurally distinct from BPC-157. Trial data showed binding to monomeric actin, which supports cellular mobility — the capacity of repair-competent cells to migrate toward a site of damage. Researchers also reported systemic distribution and reductions in pro-inflammatory cytokines including TNF-alpha in animal models. The [TB-500 research summary](https://portaltowellness.net/research/tb-500-thymosin-beta-4-research/) covers the primary literature. ### Gene expression and tissue remodelling — GHK-Cu GHK-Cu is a glycine-histidine-lysine tripeptide bound to copper, and it acts furthest upstream of the four. Preclinical research identified broad effects on gene expression, including genes governing collagen and elastin synthesis, anti-inflammatory signalling and antioxidant defence. Figures for the precise number of genes affected vary widely between secondary sources and should be treated with caution; the reproducible finding is the breadth of the expression profile, not any specific count. GHK-Cu appears in the [GLOW-70 blend](https://portaltowellness.net/shop/glow-70/) . ### GH and IGF-1 axis signalling — Ipamorelin and CJC-1295 Ipamorelin is a selective ghrelin receptor agonist; in animal studies researchers observed pulsatile growth hormone release without material effect on cortisol or prolactin. CJC-1295 is a modified GHRH analogue reported to extend the half-life of that signal. Downstream IGF-1 production is the mediator of interest, since IGF-1 coordinates repair signalling across tissue types rather than at a single site. Both are listed individually as [Ipamorelin](https://portaltowellness.net/shop/ipamorelin-10mg/) and [CJC-1295](https://portaltowellness.net/shop/cjc-1295-no-dac-10mg/) . ## Why these compounds are studied in combination A recurring question in the literature is whether these mechanisms are additive. The rationale researchers give is mechanistic non-overlap rather than potency: angiogenesis and fibroblast activation act on local repair infrastructure, actin binding acts on cell mobility, gene-expression effects act on longer-term remodelling, and GH-axis signalling sits above all three. Because those are distinct pathways, combination studies are designed to test for additive rather than redundant effects. That remains a hypothesis under investigation rather than an established result. Most combination work is preclinical, and the studies that exist vary considerably in design, model and quality. Material combining the two most-studied compounds is listed as the [BPC-157 and TB-500 injectable](https://portaltowellness.net/shop/bpc-157-tb-500-injectable/) . ## How to read this literature Four caveats apply across every compound on this page. First, animal models are not humans: rodent tendon and gastrointestinal models differ from human tissue in vascularity, loading and healing timescale, and results do not transfer automatically. Second, publication patterns favour positive findings, so the visible literature likely overstates consistency. Third, preparations are not standardised between studies, which makes cross-study comparison unreliable. Fourth, endpoints differ — histological scoring, tensile testing and biomarker panels measure different things, and studies reporting one do not necessarily agree with studies reporting another. None of that makes the literature worthless. It does mean that volume of publication is a measure of research attention rather than of established effect. ## Where the evidence is strong, and where it is thin The honest position is that this literature is largely preclinical. BPC-157 is characterised mainly in rodent gastrointestinal and soft-tissue models, and direct controlled human data is limited. The same holds for TB-500 and GHK-Cu. The GH secretagogues have a different profile again, with more human pharmacokinetic work but little controlled outcome data in repair contexts. A large volume of published animal work is not equivalent to a human evidence base — a distinction examined directly in our [recovery peptide evidence gaps](https://portaltowellness.net/research/recovery-peptide-evidence-gaps/) review. In July 2026 an FDA advisory committee voted 8-6, with one abstention, to recommend BPC-157 for the 503A bulk drug substances list. That is an advisory recommendation, not an approval, and it does not change the compound’s regulatory status. Our account of the review is the [July 2026 FDA peptide review](https://portaltowellness.net/research/fda-peptide-review-july-2026/) . ## Common research questions ### Which of these has the largest preclinical literature? BPC-157, by a clear margin, across tendon, ligament, muscle and gastrointestinal models. As above, that reflects research attention rather than effect size or transferability beyond the models studied. ### How do BPC-157 and TB-500 differ mechanistically? They differ at the cellular level. BPC-157 findings centre on angiogenesis and fibroblast activation at a local site; TB-500 findings centre on actin binding, cell migration and systemic distribution. The two are studied together precisely because those mechanisms do not overlap. ### What does the human evidence base look like? Limited. Controlled human studies in repair contexts are sparse across all four compound classes, and where human data exists it is more often pharmacokinetic than outcome-based. This is the central caveat for the entire category. ### What did the July 2026 advisory vote change? Procedurally, very little. An advisory committee recommendation informs the FDA but does not bind it, and the status of the compounds is unchanged. Its significance is that it placed this evidence base on the public record and documented where committee members disagreed. ### How is research material verified? Identity and purity documentation is the relevant question. Portal to Wellness states current testing status per compound rather than implying blanket coverage, and the position on vendor-submitted versus independently commissioned documentation is set out on the [lab testing and verification page](https://portaltowellness.net/lab-verification-quality-testing/) . Further summaries are indexed in the [Research Library](https://portaltowellness.net/research/) . --- *All compounds referenced on this page are available for research use only. They are not approved by the FDA for human use, diagnosis, therapy or prevention of any condition, and are not for veterinary use. This page is provided for informational and educational purposes. No therapeutic claims are made or implied.* --- Source: https://portaltowellness.net/recovery-repair-research-evidence/ Research use only. Terms: https://portaltowellness.net/research-use-only/